• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

    12/16/24 7:00:00 AM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LRMR alert in real time by email
    • Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study
    • Tissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90
    • Tissue FXN levels increased and were maintained over time, with mean levels increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90
    • Early trends towards improvement in clinical outcomes were observed at Day 90, supporting the potential that nomlabofusp administration may result in a clinical benefit across a broad spectrum of patients with Friedreich's ataxia (FA)
    • Pharmacokinetic (PK) data suggest that nomlabofusp levels in plasma appeared to reach steady state by Day 30 with no further accumulation following long-term daily administration
    • Dose escalation to 50 mg daily in the OLE has initiated in 6 participants to date
    • Screening of adolescents with FA is ongoing for the pediatric PK run-in study with dosing expected early 2025; adolescents who complete study participation will transition into OLE study after assessment of safety and PK data
    • Initiation of global confirmatory/registration study planned mid-2025
    • Biologics License Application (BLA) submission targeted for 2H 2025 to support potential accelerated approval
    • Strong balance sheet with $203.7 million of cash and investments as of September 30, 2024, with projected runway into the second quarter of 2026
    • Company management to host webcast and conference call today at 8:00 a.m. ET

    BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) --  Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA. The Company also provided a nomlabofusp development program update.

    "We are pleased with the advancement of our OLE study that includes 14 patients dosed for up to 260 days. Importantly, 25 mg of nomlabofusp administered daily increased and maintained tissue FXN levels over time, with mean levels increasing from 15% of healthy volunteers at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90," said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar. "Importantly, we are highly encouraged by the early trends towards improvement observed in clinical outcomes that could support the potential for nomlabofusp administration to result in a clinical benefit across a broad spectrum of patients with FA. To date we have reported data showing increases in FXN in three independent clinical studies, trends towards normalization in gene expression and lipid profiles, and we are now showing early trends in clinical outcomes. Thus, the totality of data continues to support the therapeutic potential of nomlabofusp. We are excited to be increasing the dose to 50 mg nomlabofusp daily for currently enrolled study participants as well as starting newly enrolled participants on 50 mg daily with data for the 50 mg dose expected mid-2025."

    Dr. Ben-Maimon continued, "The long-term safety, PK, and FXN data we are collecting in the OLE will be used to support a potential accelerated approval using FXN as a novel surrogate endpoint. Additionally, we are expanding clinical evaluation into adolescents with our recent initiation of our pediatric PK run-in study and expect initial data with the next update in mid-2025. Our global confirmatory and registrational study remains on track to initiate in mid-2025. Our interactions with the FDA continue to be productive and we are focused on our goal of submitting a BLA in the second half of 2025."

    Dr. Rusty Clayton, Chief Medical Officer of Larimar added, "In the OLE study, long-term dosing of nomlabofusp was generally well tolerated. While serious adverse events occurred in two study participants during the OLE study, these events resolved and both participants returned to their usual state of health within 24 hours. The information regarding these events was reviewed by our Data Monitoring Committee and submitted to FDA and the study is continuing as planned. We have initiated dosing with the 50 mg dose in six study participants and will be increasing the dose to 50 mg in all current OLE study participants and will initiate all newly enrolling participants at the 50 mg dose. We expect long-term 50 mg data, as well as initial data from adolescents completing our recently initiated pediatric PK run-in study in mid- 2025."

    "Friedreich's ataxia is caused by frataxin deficiency, and disease progression is more rapid in patients with lower frataxin levels," said Dr. Susan Perlman, Professor of Neurology and Director of the Ataxia Center, David Geffen School of Medicine at UCLA, who is one of the principal investigators in the OLE study. "Increases in frataxin levels in patients with FA may lead to the slowing of progression."

    The OLE study is evaluating the safety and tolerability, PK, and FXN levels in buccal and skin cells, along with exploratory pharmacodynamic (PD) markers (lipid profiles and gene expression data) and clinical outcomes following long-term subcutaneous administration of nomlabofusp. The participants who completed treatment in Phase 1 studies and the Phase 2 dose exploration study evaluating nomlabofusp are potentially eligible to screen for the OLE study.

    At the time of data cut off for the OLE study, 14 adults with FA were included with up to 260 days (mean 99 days) of long-term daily treatment of 25 mg of nomlabofusp. Among these patients, more than 50% were non-ambulatory.

    Key Safety Findings for Long-term 25 mg Daily Nomlabofusp

    • Generally well tolerated with two participants that had serious adverse events that resolved within 24 hours and withdrew from the study
    • Most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited

    Key FXN Data for Long-term 25 mg Daily Nomlabofusp

    • Tissue FXN levels showed mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90
    • 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of 15% of HV at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90
    • Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells



     Buccal FXN Levels (pg/μg)Skin FXN Levels (pg/μg)
    NMedianMeanNMedianMean
    Baseline111.131.1982.412.60
    Day 30112.083.6285.347.45
    Change from Baseline110.582.4382.424.85
    Day 6092.462.41   
    Change from Baseline90.531.13   
    Day 9061.892.4857.6511.73
    Change from Baseline61.011.3254.899.28

    Skin samples not collected at Day 60 per study protocol

    Only participants with quantifiable levels at each measurement point are included in the tables

    Early Trends Towards Improvement Observed Across a Number of Clinical Outcomes for Long-term 25 mg Daily Nomlabofusp

    • Decreased values indicating early trends towards improvement were observed in modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), Modified Fatigue Impact Scale, and 9 Hole Peg Test at Day 90 relative to baseline
    • Supports potential that nomlabofusp administration may result in a clinical benefit across a broad spectrum of patients with FA

    Key Pharmacokinetic Data for Long-term 25 mg Daily Nomlabofusp

    • Rapid absorption after subcutaneous administration
    • Exposure appeared to reach steady state in plasma by Day 30 with no further accumulation
    • Pharmacokinetic profile consistent with Phase 1 and Phase 2 studies

    Additional Updates on Nomlabofusp Development Program

    • Dose increased to 50 mg in OLE study in 6 study participants with plan to increase dose in all other study participants
    • Screening adolescents for pediatric PK run-in study with dosing to initiate early next year at weight-based dose equivalent of 50 mg adult dose; plan to transition adolescents who complete study participation into OLE after analysis of PK and safety data
    • Evaluating global clinical sites for planned registration/confirmatory study
    • Advancing discussions with FDA on data package required to support accelerated approval, including supplementary nonclinical pharmacology investigations, and FXN, supportive PD, and safety and clinical outcomes data from the OLE study

    Key Upcoming Catalysts

    • Q1 2025: Dose adolescents in pediatric PK run-in study (ages 12-17 years old)
    • 1H 2025: Enroll children (ages 2-11 years old) in pediatric PK run-in study
    • Mid 2025: Initiate global confirmatory/registration study
    • Mid 2025: Initial data from 50 mg dose in long-term OLE study
    • 2H 2025: BLA submission; intend to pursue accelerated approval

    Conference Call and Webcast

    Larimar will host a conference call and webcast today, December 16, 2024, at 8:00 a.m. ET. To access the webcast, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13750507 or click on this link and request a return call. Following the live event, an archived webcast will be available on the "Events & Presentations" page of the Larimar website.

    About Larimar Therapeutics

    Larimar Therapeutics, Inc. (NASDAQ:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar's ability to develop and commercialize nomlabofusp and other planned product candidates, Larimar's planned research and development efforts, including the timing of its nomlabofusp clinical trials and nonclinical investigations, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plan, and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later nonclinical or clinical trials, and assessments; that the FDA may not ultimately agree with Larimar's nomlabofusp development strategy; the potential impact of public health crises on Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar's ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

    Investor Contact:                                                        

    Joyce Allaire                                                                

    LifeSci Advisors                                                        

    [email protected]                                                 

    (212) 915-2569

    Company Contact:

    Michael Celano        

    Chief Financial Officer

    [email protected]

    (484) 414-2715                



    Primary Logo

    Get the next $LRMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LRMR

    DatePrice TargetRatingAnalyst
    1/29/2025$18.00Buy
    Truist
    10/16/2024$26.00Outperform
    Oppenheimer
    10/3/2024$22.00Outperform
    Wedbush
    10/2/2024$15.00Buy
    H.C. Wainwright
    9/4/2024$16.00Outperform
    Robert W. Baird
    4/3/2024$25.00Outperform
    Leerink Partners
    11/17/2023$4.50Neutral → Buy
    Citigroup
    10/19/2022$12.00Buy
    Guggenheim
    More analyst ratings

    $LRMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by * Director by Deputization Flynn James E

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/15/25 7:44:19 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Jeffrey W

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/14/25 4:34:08 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Truitt Joseph

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/14/25 4:33:51 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Larimar Therapeutics with a new price target

      Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00

      1/29/25 7:39:50 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Larimar Therapeutics with a new price target

      Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00

      10/16/24 7:29:15 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Larimar Therapeutics with a new price target

      Wedbush initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $22.00

      10/3/24 7:34:56 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Larimar Therapeutics Reports First Quarter 2025 Financial Results

      FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025 Strong balance sheet of $157.5 million cash, cash equivalents and marketable securities as of March 31, 2025, with projected cash runway into second quarter of 2026 BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE

      4/30/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approvalFDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and skeletal muscleLarimar is continuing discussions with FDA on the adequacy of the safety data set to support BLA submission BLA seeking accelerated approval targeted for submission by year-end 2025FDA

      3/24/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

      BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025. Details on the presentation can be found below. Date: Monday, March 10, 2025Time: 3:40 – 4:10 PM ESTWebcast Link: https://wsw.com/webcast/leerink38/lrmr/2247553 Following the conclusion of the presentation, a replay will be available for 30 days on the "Events an

      3/3/25 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 5:05:19 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 11:41:09 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 9:16:35 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Larimar Therapeutics Inc.

      SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      5/14/25 12:25:02 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      5/13/25 4:03:48 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Larimar Therapeutics Inc.

      SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      5/13/25 11:33:39 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Financials

    Live finance-specific insights

    See more
    • Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

      Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) studyTissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90Tissue FXN levels increased and were maintained over time, with mean levels increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90Early trends towards improvement in clinical outcomes were observed at Day 90, supporting the potential that nomlabofusp administration may result in a clinical benefit across a broad spectrum of patient

      12/16/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

      Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse eventsDose dependent increases in frataxin levels were observed in skin and buccal cells Open Label Extension (OLE) study initiated in January 2024 to dose 25 mg daily of nomlabofusp with dosing anticipated to be starting later this quarter; Initial data expected in Q4 2024Initiated discussions with the FDA on use of tissue frataxin levels as a novel surrogate endpoint to support a potential Biologics License Application ("BLA") submission for accelerated approval targeted for 2H 2025 Company management to host webcast and conference call today a

      2/12/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

      Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024Company management hosting a webcast and conference call today at 8:00 a.m. ET BALA CYNWYD, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601 i

      7/25/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hamilton Thomas Edward bought $499,998 worth of shares (57,208 units at $8.74), increasing direct ownership by 11% to 564,798 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/31/24 4:56:58 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flynn James E bought $37,499,993 worth of shares (4,290,617 units at $8.74) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/16/24 2:37:50 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas Frank E bought $22,000 worth of shares (2,000 units at $11.00) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/15/24 4:21:16 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

      BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy. "Dr. Sherman is a pharmaceutical industry veteran who brings decades of leadership experience in global regulatory and clinical strategy to our Board of Directors.

      10/3/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

      Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Lari

      8/10/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

      BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell "Rusty" Clayton, DO, as Chief Medical Officer ("CMO"), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. "We are delighted to welcome Dr. Clayton in his new role as CMO as we further expand our clinical development of CTI-1601. Rusty has been one of our closest advisors for the last 5 years, has attended every meeting between Larimar and the FDA, in

      7/17/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care